Navigation Links
BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
Date:1/6/2009

al product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company's leading product in development is Riquent(R), which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus renal disease is a leading cause of sickness and death in patients with lupus. The Company has also developed potential small molecule drug candidates to treat various other autoimmune and inflammatory conditions. The Company's common stock is traded on The NASDAQ Global Market under the symbol LJPC. More information about the Company is available on its Web site: http://www.ljpc.com.

This press release contains forward-looking statements, which involve significant risks, assumptions an
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.; La Jolla Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
9. Pfizer Closes La Jolla Campus Due to Continuing Fire Emergency
10. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... , , PEMBROKE, Bermuda, Dec. 4 /PRN...ny Holdings, Ltd (NYSE: AWH ) today announced th...Officer, and Jack Sennott, Executive Vice,Presiden...esenting at the 2009,Goldman Sachs U.S. Financial ...s Conference Center in New York City on Tuesday, D...
(Date:12/4/2009)... , , MADISON HEIGHTS, Mich., Dec...urities Review Committee of BetterInvesting Magaz... ) as its February 2010 "Stock to Study" and C.R....Undervalued Stock" for investors, informational an...rgan because of growth opportunities involving its...
(Date:12/4/2009)... , Late recurrence is a risk for some pediatric c...the central nervous system, according to a new stu...the National Cancer Institute . , This study was...ate recurrence (after 5 years and up to 20 years) ...i-Masker, M.D., of the Aflac Cancer Center and Blo...
(Date:12/4/2009)... , More than 15 million Americans are recruited...ing to the Alliance for Human Research Protection ...ticipation. , Research institutions view pay...xpenses; not as compensation for potential risks r... new study finds that volunteers have a very diffe...
(Date:12/4/2009)... Increasing exercise, water and fruit consumptio...IDAY, Dec. 4 (HealthDay News) -- Increased exercis...among the most effective weight control strategies...ers surveyed 130 adolescents about their weight-co...ad succeeded in losing weight and 68 had not. The ...
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Teens Lose More Weight Using Healthy Strategies 2
...genital Heart Disease published recently in the Eu...ty of adult heart care and the extent of its defic...improvement in the treatment of pediatric heart di...of the patients and list the deficient areas. 71 c...
... by researchers at Columbia University Medical Cen... rates and adherence to cancer treatment, //it has...had stopped their chemotherapy. More specifically,...efore completion. Non-compliance rates in th...
...rs at University of Manchester now reveals that sp...iseases, Vascular Dementia and Alzheimer's disease...sh Medical Journal (BMJ). This finding could e...d vascular dementia can account for a major propor...
...n 2004 the sales of Celebrex was $3.3 billion worl...g causing heart attacks the company stopped advert...he consumer ad market in hopes of reviving sales o...oost it sales. Each ad includes a boldface warnin...
...quently among children. It is one of the diseases ...ow 3 months of age//. Hence Dr. Lawrence S. Eichen...an Diego and colleagues came up with the fluticaso...en compared to ointments and creams. It is very he...
...ssion of senile amyloidosis to offspring from affe...om mother to child// have been raised. Details abo...is in offspring of mice with AApoAII amyloidosis,'...including amyloidosis. Amyloidosis occurs when cel...
Other Medicine News:Health News:Colon Cancer Death Rate Doubles As Patients Stop Chemotherapy 2Health News:Doubts About In UteroTransmission Of Senile Amyloidosis 2
(Date:12/3/2009)...DOYLESTOWN, Pa., Dec. 3 ...ation, (Nasdaq: QGLY ) www.quigleyco.com announ...ation of its opportunities to develop prescription... that it is in its best interests to focus primari... include but are not limited to its Cold-EEZE®...
(Date:12/3/2009)..., WARRENDALE, Pa., Dec. 3 Radiol... injection-record integration capabilities at the ...n Chicago. The Connect.PACS(TM) product, enabli... its kind, is the latest release in the company,s ... ,, (Photo: http://www.newscom.com/cgi-bin/...
(Date:12/3/2009)..., HOERSHOLM, Denmark and SAN DIEGO, Californi... Successfully Inhibits miR-122, a microRNA Importa...ificantly Reducing Hepatitis C,Virus in the Bloods...,Hepatitis C Virus , - SPC3649 Demonstrat...nd,No Serious Adverse Events in the Treated Animal...
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 1Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 2Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 3Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 4Genes May Raise Risk of Neuroblastoma in Kids 49265 1Genes May Raise Risk of Neuroblastoma in Kids 49265 2Genes May Raise Risk of Neuroblastoma in Kids 49265 3Berlin Heart Inc Receives FDA Orphan Product Development Grant 12679 1Berlin Heart Inc Receives FDA Orphan Product Development Grant 12679 2
...AL GABLES, Fla., Jan. 9 Catalyst,Pharmaceutical P...al company that,acquires, in-licenses, develops an...ent of drug addiction, announced today that it has...e II trial evaluating CPP-109 for the treatment,of...ormulation of vigabatrin,being developed as a trea...
... Switzerland, Jan. 9 ESBATech AG, a leading develo...nced the initiation of the Phase I/IIa clinical de...ESBA105 in osteoarthritis (OA). This double-blind,...al study is designed to investigate the safety, to...ed locally via intra-articular administration to p...
Other Medicine Technology:Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial 2Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial 3ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 2ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 3ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 4
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: